Chicago Atlantic BDC, Inc. (LIEN) stock intrinsic value fair value estimate & owner earnings analysis

What the business is. Chicago Atlantic BDC (formerly Silver Spike Investment Corp.) is a small, externally managed business development company. It makes short-dated senior secured loans, mainly to state-licensed cannabis operators. It does not grow or sell cannabis. It is a lender, and its unusually high yields (16.0% on its debt investments at 30 June 2026) exist because cannabis is still illegal under federal law, so most banks will not lend to these borrowers. The business changed completely on 1 October 2024. On that date it issued 16.6 million shares to buy a $219.6 million loan portfolio from an affiliate of its adviser, Chicago Atlantic, and took on that firm's lending platform. Before that it was an $85 million fund with 6.2 million shares, so we measure the business from that date. At 30 June 2026 it held $334.8 million of loans across 37 borrowers, against $302.5 million of net assets, or $13.26 a share. Earnings. We use the cash the loan book produces for shareholders. New loans and repayments are a lender's stock-in-trade, not an expense, so we leave them out. We also leave out interest that borrowers add to their loan balance instead of paying in cash ($2.6 million in 2025) and the non-cash accretion of loan discounts ($2.7 million). On that basis 2025, the first full year on the enlarged portfolio, produced $28.4 million, or $1.25 a share, against reported net investment income of $1.45. There is no stock compensation and no capital spending. We make two adjustments to that level. First, in 2025 the adviser absorbed about $2.0 million of expenses under a cap that expired on 30 September 2025 and was not renewed. That is about $0.09 a share that will not recur. Second, we charge an ongoing credit cost of 1% of the loan book a year, about $0.15 a share. Through 2025 the company had no loans on non-accrual, but the first half of 2026 brought about $3.0 million of declines in loan values. That is the first real credit cost on this book, and a lender with the borrowers it has should expect some losses. That leaves a normal level of about $1.01 a share. The quarterly pattern confirms this is not a growth story: first-quarter 2026 net investment income was $0.44 a share, helped by early repayments, and the second quarter was $0.34. Earnings per share rose sharply in 2025, but that came from the portfolio purchase and is not growth the business can repeat. So every case starts flat, and year 1 of the base case assumes no growth. Interest rates. About 72% of the loans float, but 63% of those were at their interest-rate floors at the end of 2025. The company's own disclosure shows a 3-point fall in rates would cut annual net investment income by only about $0.4 million. Falling rates are therefore a small risk. The real risks are credit and regulation. The three largest borrowers made up 31.8% of the portfolio at the end of 2025, and the largest alone 15.7%. Cannabis licenses generally cannot be pledged as collateral, so recoveries in a default could be poor. In December 2025 a presidential executive order directed the Attorney General to speed up moving cannabis to Schedule III. The company notes this would ease borrowers' tax burden, which helps credit, but would not make state cannabis programs legal under federal law. Over time it points toward more lenders and lower spreads. Base case, $14.53 a share. Earnings stay at about $1.01 a share for six years. Over years 7 to 10 they fade to about $0.80, roughly 6% of net assets, which is what an ordinary senior lender with this little borrowing earns, as rescheduling and possible banking access bring in competition. After year 10 we credit only the loan book itself at net asset value of $13.26, with no premium, because nothing we can point to today guarantees above-market spreads beyond that. The earnings stream is worth about $7.12 a share and the returned loan book about $7.40. Bear case, $11.91. Cannabis lending has not been through a full credit cycle as an institutional asset class. We therefore take the downturn from the disclosed concentration and the weak collateral position: two of the large borrowers default within three years and about 10% of the portfolio is lost. That is roughly $1.47 of net asset value per share, taking it to about $11.79. Lost interest on the defaulted loans plus reserve building cuts earnings to about $0.70 a share in years 1 and 2 and $0.85 in year 3. Spreads then fall to ordinary levels, about $0.71 a share (6% of the smaller net assets), and the loan book is returned at $11.79. The earnings stream is worth about $5.32 and the loan book about $6.58. Bull case, $16.46. Loan losses run at half the base-case rate, about $0.07 a share. The company keeps using its $100 million Western Alliance credit facility to fund loans from its reported $732 million pipeline, which adds about $0.14 a share after borrowing costs. Earnings are about $1.23 a share for ten years at today's spreads, and then the loan book is returned at $13.26. Debt. Because lending is the business, we value it after its interest costs and do not subtract the borrowings a second time. Borrowing is small: $27.0 million was drawn on the credit facility at 30 June 2026, rising to $53.5 million by 12 August, against about $302 million of net assets. The facility charges one-month SOFR plus 3.00%, allows new draws until 11 February 2027 and matures on 31 March 2028. Loan repayments could retire it in every case, including the bear case, so refinancing is not a serious risk. No case depends on the debt being rolled over. The pending merger. On 17 June 2026 the company agreed to merge with Chicago Atlantic Real Estate Finance, a sister lender run by an affiliate of the same adviser. Shares will be exchanged at the two companies' net asset values set shortly before closing. On 31 March 2026 values, former Real Estate Finance holders would own about 50.5% of the combined company. Both sets of shareholders must approve, and closing is expected in the fourth quarter of 2026. A swap at net asset value does not by itself change value per share, so we have kept the merger out of all three cases. It would, however, double the size of the business and add a second loan book with its own borrowers. The terms of the new advisory agreement have not been disclosed. Once the deal closes, the combined loan book and fee terms will need to be valued afresh. The margin-of-safety price. We are fairly confident of the earnings level: it rests on a full year and a half of the enlarged portfolio, the fees and yields have been steady, and we have already removed the expired expense cap and charged for losses. We are less sure of credit. The worst plausible outcome is a default by the largest borrower, at 15.7% of the book, with a deep loss because cannabis licenses cannot be seized, at the same time as federal enforcement against state programs, which the company lists as a risk. That would cut net asset value by more than our bear case. But the company has little debt, its loans are short-dated, and it is required to pay out most of its income, so it would survive and keep returning cash. The two things we are most likely to be wrong about are the size of credit losses and how long the cannabis lending premium lasts. If losses run at twice the base rate and spreads normalize by year 4, the shares would be worth roughly the bear figure of about $12. The business pays out cash during the holding period: it has paid $0.34 a share every quarter for seven quarters, and our base case supports about $1.01 a year. The margin-of-safety price is $9.00. From that price, if the base case holds and the shares come back to net asset value of $13.26 within three years, the base case implies about 24% a year including about $1.01 a year of payouts. The bear case, with net asset value falling to $11.79, implies about 17% a year over three years, and more if the recovery comes sooner. The price is set with that bear-case cushion because a single large default is the most likely way this goes wrong. Compared with our previous analysis. Our earlier estimates were $12.24, $14.95 and $17.12. Two things have moved since then. First, we now remove the roughly $0.09 a share of 2025 expenses that the adviser absorbed under the cap that expired in September 2025. That lowers the base and bull cases. Second, the pending merger has been announced, but we have kept it out of the numbers for the reasons above. The bear case is slightly lower because it now also carries the loss of the expense cap. The lower margin-of-safety price reflects the bear case: it is set so that the bear case approaches a 20% return even if two large borrowers fail.